Yaz›flma Adresi / Address for Correspondence
Yüklə 320,6 Kb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- [CrossRef]
- [Cross- Ref]
|
[CrossRef] 94. Puri P. Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis. J Clin Exp Hepatol. 2013; 3(4): 301-12. [CrossRef] 95. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus state- ment on the management of chronic hepatitis B: a 2008 update.
96. Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failu- re: consensus recommendations of the AsianPacific Association for the Study of the Liver (APASL). Hepatol Int. 2009; 3(1): 269-82. [CrossRef] 97. Lok AS, Mahon MJ. Chronic hepatitis B: update 2009. Hepato- logy. 2009; 50(3): 661-2. [CrossRef] 98. Wai-Sun V, Lik-Yuen Chan H. Severe acute exacerbation of chro- nic hepatitis B: A unique presentation of a common disease. J
99. Han Y,Tang Q, Zhu W, Zhang X,You L. Clinical, biochemical, im- munological and virological profiles of, and differential diagno- sis between, patients with acute hepatitis B and chronic hepa- titis B with acute flare. J Gastroenterol Hepatol. 2008; 23(11): 1728-33. [CrossRef] 100. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N.Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol. 2006; 37(3): 206-12.
101. Dao DY, Hynan LS, Yuan H-J, et al. Two distinct subtypes of he- patitis B virus-related acute liver failure are separable by quan- titative serum immunoglobulin M antihepatitis B core antibody and hepatitis B virus DNA levels. Hepatology. 2012; 55(3): 676- 84.
[CrossRef] 102. Jeng WJNG, Sheen IS, Liaw YF. Hepatitis B virus DNA level pre- dicts hepatic decompensation in patients with acute exacerbati- on of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010; 8(6): 541-5.
103. Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Cha- muleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mor- tality. Liver Int. 2013; 33(1): 40-52.
104. Wong GL, Wong, VW, Choi PC, et al. Increased liver stiffness me- asurement by transient elastography in severe acute exacerba- tion of chronic hepatitis B. J Gastroenterol Hepatol. 2009; 24(6): 1002-7.
105. Liang XE, Chen YP, Zhang Q, Zhu YF, Hou JL. Dynamic evaluation of liver stiffness measurement to improve diagnostic accuracy of liver cirrhosis in patients with chronic hepatitis B acute exa- cerbation. J Viral Hepat. 2011; 18(12): 884-91.
106. Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int. 2013: 33(1): 164-75.
107. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351(15): 1521-31. [CrossRef] 108. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J
109. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellu- lar carcinoma: old and new paradigms. Gastroenterology. 2004; 127(5): 56-61. [CrossRef] 110. Türkiye Karaciğer Araştırmaları Derneği Hepatiti B Çalışma Gru- bu. Türkiye Hepatit B Yol Haritası. İstanbul: Türkiye Karaciğer Araştırmaları Derneği, 2012: 1-26. 111. Nguyen T, Locarnini S.Hepatitis: monitoring drug therapy for hepatitis B-a global challenge? Nat Rev Gastroenterol Hepatol. 2009; 6(10): 565-7.
112. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virologi- cal response to lamivudine. Hepatology. 2004; 40(4): 883-91. [CrossRef] 113. Lai CL, Chien RN, Leung NW, et al. A-one year trial of lamivu- dine for chronic hepatitis. N Engl J Med. 1998; 339(2): 61-8.
114. Fasano M, Lampertico P, Marzano A, et al. HBV DNA suppressi- on and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol. 2012; 56(6):1254-8.
115. Rivkin AM. Adefovir dipivoxil in the treatment of chronic hepati- tis B. Ann Pharmacother. 38(4): 625-33.
116. Köksal İ. Kronik hepatit B’de genel tedavi yaklaşımı. In: Tabak F, Tosun S, eds. Viral Hepatit 2013. Ankara: Viral Hepatitle Savaşım Derneği, 2013: 257-64. 117. Hsu CW, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of tel- bivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outco- me by HBV DNA kinetics at week 24. BMC Gastroenterol. 2012; 12: 178.
118. Gane EJ, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
119. Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014; 146(1): 138-46. [CrossRef] 16
Klimik Dergisi 2014; 27(Özel Sayı 1): 2-18 120. Wu YK, Li XY, Lin GL, et al. Comparison of the efficacy of lami- vudine, adefovir dipivoxil, telbivudine and entecavir in treating NAs-naive patients with chronic HBV infection: 4-year real life data [Abstract]. Hepatology. 2012; 56(Suppl. l): 377. 121. Luo J, Li X, Wu Y, et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci. 2013; 10(4): 427-33.
122. Marcellin P, Gane EJ, Tsai N, et al. Seven years of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infecti- on is safe and well tolerated and associated with sustained virolo- gical, biochemical, and serological responses with no detectable resistance [Abstract]. Hepatology. 2013; 58(Suppl. 1): 926. 123. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis du- ring treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381(9865): 468-75. [CrossRef] 124. Viral Hepatitle Savaşım Derneği. III. Viral Hepatit Tanı ve Tedavi Rehberi (10 Aralık 2014) [İnternet]. Ankara: Viral Hepatitle Sa- vaşım Derneği [erişim 5 Şubat 2014]. http://www.vhsd.org/files/ file/rehberler/3_Viral_Hepatit_Tani_ve_Tedavi_Rehberi2.pdf. 125. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lami- vudine, and the combination for HBeAg-positive chronic hepati- tis B. N Engl J Med. 2005; 352(26): 2682–95. [CrossRef] 126. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated inter- feron alfa-2b alone or in combination with lamivudine for HBe- Ag-positive chronic hepatitis B: a randomised trial. Lancet. 2005; 365(9454): 123-9.
127. Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbi- vudine is superior to lamivudine in patients with chronic hepati- tis B. Gastroenterology. 2009; 136(2): 486-95. [CrossRef] 128. Mealing S, Ghement I, Hawkins N, et al. The importance of ba- seline viral load when assessing relative efficacy in treatment- naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Syst Rev. 2014; 3: 21.
129. Yan LB, Chen EQ, Bai L, et al. Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load. Clin Res Hepatol Gast- roenterol. [Baskıda]. 130. Lampertico P, Vigano` M, Colombo M. Treatment of HBeAg-ne- gative chronic hepatitis B with pegylated interferon. Liver Int. 2011; 31(Suppl. 1): 90-4. [CrossRef] 131. Lin CL, Kao JH. The clinical implications of hepatitis B virus genoty- pe: recent advances. J Gastroenterol Hepatol 2011; 26 (1): 123-30.
132. Leblebicioglu H, Eroglu C, Members of the Hepatitis Study Gro- up. Acute hepatitis B virus infection in Turkey: epidemiology and genotype distribution. Clin Microbiol Infect. 2004; 10(6): 537-41. [CrossRef] 133. Karabay O, Tuna N, Esen S; PEG-HBV Study Group. Comparative efficacy of pegylated interferons a-2a and 2b in the treatment of HBeAg-negative chronic hepatitis B infection. Eur J Gastroente- rol Hepatol. 2012; 24(11): 1296-301. [CrossRef] 134. Hadziyannis SJ. Treatment paradigms on hepatitis B e anti- gen-negative chronic hepatitis B patients. Expert Opin Investig
135. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125(6): 1714-22. [CrossRef] 136. Zuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict 3 the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol. 2009; 51(1): 11-20.
137. Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013; 20(4): 37-46. [CrossRef] 138. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepa- titis B for up to 5 years. Gastroenterology. 2006; 131(6): 1743–51. [CrossRef] 139. Viganò M, Mangia G, Lampertico P. HBeAg-negative chronic he- patitis B: why do I treat my patients with nucleos(t)ide analogu- es? Liver Int. 2014; 34(Suppl. 1): 120-6. [CrossRef] 140. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histo- logical improvement in patients with chronic hepatitis B. Hepa- tology. 2010; 52(3): 886-93. [CrossRef] 141. Corsa AC, Liu Y, Flaherty JF, et al. No resistance to tenofovir di- soproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol. 2014; 12(12): 2106-12. [CrossRef] 142. Marcellin P, Heathcote EJ, But M, et al. Tenofovir disoproxil fu- marate versus adefovir dipivoxil for chronic hepatitis B. N Engl J
143. Kitrinos KM, Korsa A, Liu Y, et al. No detectable resistance to teno- fovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014; 59(2): 434-42. [CrossRef] 144. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006; 44(3): 593-606. [CrossRef] 145. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced anti- genicity of the hepatitis B virus HBsAg protein arising as a con- sequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology. 2002; 293(2): 305-13. [CrossRef] 146. Locarnini SA, Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther. 2010; 15(3): 451-61.
147. Niesters HGM, Pas S, de Man RA. Detection of hepatitis B vi- rus genotypes and mutants: current status. J Clin Virol. 2005; 34(Suppl. 1): S4-8. [CrossRef] 148. Locarnini SA. Clinical relevance of viral dynamics and genoty- pes in hepatitis B virus. J Gastroenterol Hepatol. 2002; 17(3): 322-28.
[CrossRef] 149. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002; 25(2): 97-106. [CrossRef] 150. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedderd RS, Tor- resi J. Global control of hepatitis B virus: does treatment-indu- ced antigenic change affect immunization? Bull World Health Organ. 2010; 88(1): 66-73. [CrossRef] 151. Thibault V, Olivier CA, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS. 2002; 16(1): 131-3.
152. Nijhuis M, van Maarseveen NM, Boucher CAB. Antiviral resis- tance and impact on viral replication capacity: evolution of viru- ses under antiviral pressure occurs in three phases. Handb Exp Pharmacol. 2009; 189: 299-320. [CrossRef] 153. Sayan M, Akhan SÇ, Şenturk Ö. Frequency and mutation pat- terns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogues in add-on and switch stra- tegies. Hepat Mon. 2011; 11(10): 835-42.
154. Sayan M, Akhan SÇ. Antiviral - drug - associated potential vac- cine - escape hepatitis B virus mutants in Turkish patients with
chronic hepatitis B. Int J Infect Dis. 2011; 15(10): 722-6. [Cross- Ref] 155. Sayan M, Şentürk Ö, Akhan SÇ, Hülagü S, Çekmen MB. Monito- ring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analogues resistance mutations in Turkish patients with chronic hepatitis B infection. Int J Infect
156. Sayan M, Akhan SÇ, Meriç M. Naturally occurring amino - acid substitutions to nucleos(t)ide analogues in treatment naive Tur- kish patients with chronic hepatitis B. J Viral Hepat. 2010; 17(1): 23-7.
157. Sayan M, Cavdar C, Dogan C. Naturally occurring polymerase and surface genes variants of hepatitis B virus in Turkish hemo- dialysis patients with chronic hepatitis B. Jpn J Infect Dis. 2012; 65(6): 495-501.
158. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61(4):766-8.
159. Sayan M. Molecular diagnosis of entecavir resistance. Hepat Mon. 2010; 10(1): 42-7. 160. Sayan M, Hülagü S, Karataylı SC. Multidrug-resistant hepatitis B virus strain in a chronic Turkish patient. Hepat Mon. 2010; 10(2): 141-6.
161. Sayan M, Hülagü S, Akhan SÇ, Şentürk Ö, Meriç M, Çekmen MB. Lamivudin tedavisi uygulanmış ve entekavir naif kronik hepatit B’li hastalarda entekavir ilaç direnci. Mikrobiyol Bül. 2009; 43(3): 425-32. 162. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137(5): 1593-608.
163. Locarnini S. Transmission of antiviral drug resistant hepatitis B virus: Implications for public health and patient managment. J
164. World Health Organization Executive Board. Viral hepatitis. Re- port by the Secretariat. EB126/15. Geneva: WHO, 2009. 165. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive im- munization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16): 1-33. 166. Tosun S. Hepatit B aşılaması. Dünyadaki ve ülkemizdeki durum. In: Tabak F, Balık İ, eds. Viral Hepatit 2009. Ankara: Viral Hepatitle Savaşım Derneği, 2009: 307-51. 167. Bruce M, Bruden DJ, Hurlburt D, et al. Antibody levels and pro- tection after hepatitis B vaccine: results of 30-year follow-up study and response to a booster dose [Abstract]. Hepatology. 2013; 58(Suppl. 1): 187. 18 Klimik Dergisi 2014; 27(Özel Sayı 1): 2-18 Yüklə 320,6 Kb. Dostları ilə paylaş:
|